Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 72, n° 2
pages 302-309 (février 2015)
Doi : 10.1016/j.jaad.2014.10.028
accepted : 22 October 2014
Original Articles

Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: A Rochester Epidemiology Project population-based study in Minnesota

Jerry D. Brewer, MD a, , Tait D. Shanafelt, MD b, Farzaneh Khezri, MD a, Ivette M. Sosa Seda, MD a, Adeel S. Zubair, BS f, Christian L. Baum, MD a, Christopher J. Arpey, MD a, James R. Cerhan, MD, PhD c, Timothy G. Call, MD b, d, Randall K. Roenigk, MD a, Carin Y. Smith, BS e, Amy L. Weaver, MS e, Clark C. Otley, MD a
a Department of Dermatology, Mayo Clinic, Rochester, Minnesota 
b Division of Hematology, Mayo Clinic, Rochester, Minnesota 
c Division of Epidemiology, Mayo Clinic, Rochester, Minnesota 
d Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 
e Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota 
f Mayo Medical School, Mayo Clinic College of Medicine, Rochester, Minnesota 

Reprint requests: Jerry D. Brewer, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.

Cutaneous malignancy is associated with worse outcomes in patients with chronic lymphocytic leukemia (CLL).


We sought to identify the incidence and recurrence rate of nonmelanoma skin cancer (NMSC) in patients with non-Hodgkin lymphoma (NHL).


NMSC incidence was calculated and Cox proportional hazards models were used to evaluate associations with risk of recurrence for patients with NHL between 1976 and 2005 who were in the Rochester Epidemiology Project research infrastructure.


We identified 282 patients with CLL or small lymphocytic lymphoma and 435 with non-CLL NHL. The incidence of basal cell carcinoma and squamous cell carcinoma was 1829.3 (95% confidence interval [CI] 1306.7-2491.1) and 2224.9 (95% CI 1645.9-2941.6), respectively, in patients with CLL. The cumulative recurrence rate at 8 years after treatment with Mohs micrographic surgery was 8.3% (95% CI 0.0%-22.7%) for basal cell carcinoma and 13.4% (95% CI 0.0%-25.5%) for squamous cell carcinoma in patients with CLL.


This was a retrospective cohort study.


After Mohs micrographic surgery and standard excision of NMSC, patients with NHL had a skin cancer recurrence rate that was higher than expected. Careful treatment and monitoring of patients with NHL and NMSC are warranted.

The full text of this article is available in PDF format.

Key words : chronic lymphocytic leukemia, immunosuppression, malignant melanoma, Mohs micrographic surgery

Abbreviations used : BCC, CI, CLL, NHL, NMSC, REP, SCC

 Supported in part by a Dermatology Foundation Career Development Award for the study of lymphoma-associated skin cancer (Dr Brewer).
 Conflicts of interest: None declared.

© 2014  American Academy of Dermatology, Inc.@@#104156@@